Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: Treatment with atomoxetine

Clinical Pediatrics

Volumn 54, Issue 2, 2015, Pages 164-173

  Wietecha, Linda A ^a   Wang, Shufang ^a   Saylor, Keith E ^b   Day, Kathleen A ^a   Wu, Sheng Hu ^c   Kelsey, Doug ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Spring Park Technology Center   (United States)

^c Eli Lilly Asia Inc   (China)

Author keywords

ADHD; atomoxetine; classification and regression tree (CART) analysis; growth mixture modeling (GMM) analysis

Indexed keywords

ATOMOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RATING SCALE; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SEX RATIO; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROPYLAMINES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 84921021519     PISSN: 00099228     EISSN: 19382707     Source Type: Journal    
DOI: 10.1177/0009922814555973     Document Type: Article

References (24)

1. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 ; 19: 353-364
2. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord. 2000 ; 3: 200-211
3. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004 ; 14: 11-28
4. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 642-657
5. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004 ; 7: 77-97
6. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005 ; 44: 647-655
7. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyper-activity disorder. J Clin Psychiatry. 2002 ; 63: 1140-1147
8. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 ; 108: E83
9. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyper-activity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009 ; 48: 511-518
10. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006 ; 29: 1573-1585
11. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003 ; 31: 98-107
12. Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila). 2009 ; 48: 723-733
13. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004 ; 114: e1 - e8
14. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, NY: Guilford Press ; 2014 :
15. Clinical Global Impressions. Psychopharmacol Bull. 1985 ; 21: 839-943
16. Guy W ECDEU Assessment Manual for Psychopharma-cology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare ; 1976 :
17. Muthén B Handbook of Quantitative Methodology for the Social Sciences. Kaplan D, ed. Thousand Oaks, CA: Sage ; 345-368.
18. Breiman L, Friedman JH, Olshen RA, Stone CJ Classification and Regression Trees. New York, NY: Chapman & Hall ; 1984 :
19. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998 ; 26: 257-268
20. Landgraf JM, Abetz L, Ware JE The CHQ User's Manual. 1 st ed. Boston, MA: Health Institute, New England Medical Center; 1996. Boston, MA: Health Institute, New England Medical Center ; 1996 :
21. Saylor K, Buermeyer C, Sutton V, Faries D, Khan S, Schuh K. The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder-Child Version: psychometric properties of an adaptive change instrument. J Child Adolesc Psychopharmacol. 2007 ; 17: 831-842
22. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 ; 159: 1896-1901
23. Indianapolis, IN: Eli Lilly and Company ; 2014 :
24. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008 ; 165: 721-730